Post-Marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Syrup Among Filipino Pediatric Patients.

Trial Profile

Post-Marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Syrup Among Filipino Pediatric Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Oct 2014

At a glance

  • Drugs Desloratadine (Primary)
  • Indications Allergic rhinitis; Urticaria
  • Focus Adverse reactions
  • Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 27 Jan 2012 Trial phase changed from II to III as reported by ClinicalTrials.gov.
    • 27 Jan 2012 Actual patient number (2980) added as reported by ClinicalTrials.gov.
    • 22 Sep 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top